Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 13/20 | 0.53 |
| ▸ | AKT2 | P31751 | 12/20 | 0.53 |
| ▸ | AKT3 | Q9Y243 | 12/20 | 0.53 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13229960 | 0.91 | AKT1 (0.51) | AKT1AKT2AKT3AKT1S1KMT2A | |
| SCHEMBL2797356 | 0.83 | MALT1 (0.44) | AKT1AKT2AKT3AKT1S1KMT2A | |
| Hydrochloric Acid SCHEMBL2797475 | 0.72 | LMNA (0.65) | AKT1AKT2AKT3AKT1S1MALT1 | |
| SCHEMBL2795640 | 0.72 | LMNA (0.64) | AKT1AKT2AKT3MALT1LMNA | |
| SCHEMBL6605083 | 0.71 | MEN1 (0.49) | KMT2ALMNACYP2D6GAA | |
| SCHEMBL2795162 | 0.69 | AKT1 (1.00) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL15617934 | 0.69 | AKT1 (1.00) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL6017353 | 0.69 | AKT1 (0.73) | AKT1AKT2AKT3AKT1S1 | |
| SCHEMBL15963333 | 0.69 | CYP1A2 (0.59) | AKT1AKT2AKT3AKT1S1MALT1 | |
| SCHEMBL2797182 | 0.69 | AKT1 (0.68) | AKT1AKT2AKT3AKT1S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148436-A1 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
| US-20160152576-A9 | AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885AKT3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.